Company intelligence / Profile preview
Prokarium
London, England, United Kingdomprokarium.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Prokarium's lead program ZH9 received FDA IND approval in November 2023 for non-muscle invasive bladder cancer. The PARADIGM-1 clinical trial is currently enrolling patients across multiple centers in the United States.
- Therapeutic areas
- Oncology
- Modalities
- Microbial immunotherapySalmonella-based therapeuticsRNA therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Ginkgo BioworksWacker Biotech
Beyond the preview
Go deeper on Prokarium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prokarium.